What is the optimal management strategy for hemochromatosis, including therapeutic phlebotomy and iron chelation therapy?

Hemochromatosis Management

Therapeutic phlebotomy is the first-line treatment for hemochromatosis and should be initiated weekly or biweekly with a target ferritin of 50 μg/L during the induction phase, followed by maintenance phlebotomy to keep ferritin between 50-100 μg/L. 1

Treatment Algorithm

Induction Phase (Iron Depletion)

Phlebotomy Protocol:

• Remove 500 mL blood weekly or biweekly as tolerated 1, 2
• Check hemoglobin/hematocrit before each session
• Pause if hemoglobin drops below 11 g/dL; reduce frequency if below 12 g/dL 1
• Do not allow hemoglobin to fall more than 20% from baseline 2
• Monitor ferritin after every 4 phlebotomies until reaching 200 μg/L, then check every 1-2 sessions 1
• Target ferritin: 50 μg/L 1
• Duration may extend 2-3 years in patients with >30 g total body iron stores 2

Critical Point: Morbidity and mortality are significantly reduced when treatment begins before cirrhosis or diabetes develops 1. Treatment initiated early can improve survival, potentially reverse liver fibrosis in some patients, and improve fatigue and liver function tests 1.

Maintenance Phase (Prevent Reaccumulation)

• Frequency varies widely: typically 2-6 phlebotomies per year 1
• Some patients require monthly sessions; others need only 1-2 units annually 2
• Check hemoglobin before each session
• Monitor ferritin and transferrin saturation every 6 months 1
• Target ferritin: 50-100 μg/L 1, 2
• Life-long follow-up required 1

Important caveat: Not all patients reaccumulate iron at the same rate, so maintenance frequency must be individualized based on ferritin monitoring 2.

Alternative Treatment Options

Erythrocytapheresis

When to consider: Available as a therapeutic alternative, particularly beneficial in selected cases 1

Advantages over phlebotomy:

• Fewer hemodynamic changes 1
• Fewer procedures needed during induction phase 1
• Returns valuable blood components 1
• May reduce fatigue more effectively 1

Disadvantages:

• Mild citrate reactions are common 1
• Depends on local availability and expertise 1
• Cost-effectiveness varies (personalized approach is superior to fixed-volume) 1

Target ferritin: Same as phlebotomy (Induction: 50 μg/L; Maintenance: 50-100 μg/L) 1

Iron Chelation Therapy

Use only as second-line treatment when phlebotomy is not feasible 1

Indications:

• Patients who cannot tolerate phlebotomy
• Severe juvenile hemochromatosis (especially induction phase) 1
• Anemic patients where phlebotomy is contraindicated 2

Critical warning: Oral deferasirox (most studied chelator in hemochromatosis) should NOT be used in patients with advanced liver disease 1. It carries risks of gastrointestinal side effects and kidney impairment 1. Deferasirox is not approved by the European Medicines Agency for hemochromatosis treatment 1.

For secondary iron overload (transfusion-dependent): Deferoxamine (parenteral) at 20-40 mg/kg/day or oral deferasirox are standard 2

Essential Patient Counseling

Dietary modifications do NOT substitute for iron removal therapy 1

Must avoid:

• Iron supplements 1, 2
• Vitamin C supplements (accelerates toxic iron mobilization, especially during phlebotomy) 2
• Daily red meat consumption 1
• Moderate to heavy alcohol intake 1
• Raw or undercooked seafood (Vibrio vulnificus risk) 1, 2
• Contact of wounds with seawater 1

For advanced liver disease: Complete alcohol abstinence required 1

Helpful adjunct: Proton-pump inhibitors (when prescribed for other indications) can reduce phlebotomy requirements 1

Special Considerations

Patients with Advanced Disease

Cardiac involvement warning: Patients with cardiac arrhythmias or cardiomyopathy face increased risk of sudden death with rapid iron mobilization 2. Recent evidence shows phlebotomy can improve systolic and diastolic dysfunction even in end-stage cardiac hemochromatosis 3.

Cirrhosis: Advanced cirrhosis is not reversed by iron removal 2. Decompensated liver disease is an indication for liver transplantation evaluation 2. Adequate iron removal before transplant is critical to prevent perioperative cardiac and infectious complications 2.

Blood Donation

Patients with uncomplicated hemochromatosis (without significant organ damage) can serve as regular blood donors during maintenance phase 1. Blood from hemochromatosis patients is safe for transfusion and approved by regulatory agencies 2.

Monitoring for Treatment Failure

Red flags requiring complete workup:

• Development of iron deficiency anemia 1
• Unexplained reduction in phlebotomy need 1

These suggest alternative causes and warrant investigation.

Common Pitfalls to Avoid

1. Do not aim for iron deficiency - target is ferritin 50-100 μg/L, not complete depletion 2
2. Do not recommend dietary iron restriction as primary therapy - the impact is minimal (2-4 mg/day) compared to phlebotomy (250 mg/week) 2
3. Do not use chelation as first-line unless phlebotomy is truly contraindicated 1
4. Do not give vitamin C supplements - particularly dangerous in iron-loaded patients undergoing phlebotomy 2

The 2022 EASL guidelines 1 represent the most current and comprehensive evidence, superseding the 2011 AASLD guidelines 2, though both align on core principles of phlebotomy as first-line therapy with specific ferritin targets.